Assessing the impact of glaucoma and its treatment on the person

 描述(申请人提供)：青光眼是全球和美国视力受损和失明的主要原因之一。虽然青光眼通常是一种影响双眼的疾病，但在典型的眼车环境中，对其对患者影响的临床评估是在每只眼睛上单独进行的。这掩盖了这样一个事实，即受青光眼影响的人双眼都有功能，用于控制青光眼的治疗可能会对人产生影响，而不仅仅是对眼睛产生影响，即使这些治疗只对一只眼睛进行。这项研究的主要目的是评估青光眼对人的影响，而不是对眼睛的影响。青光眼一直与抑郁相关，因此我们打算评估新诊断的青光眼患者从确诊时起通过9年的治疗期间的随访，关于其患病率和预测因素的评估。治疗青光眼的典型方法是频繁地(通常每天两到三次)服用一种或多种局部药物(眼药水)来控制眼压。每种类型的药物都有一组与其使用相关的独特的潜在症状。我们希望将所报告的眼部和全身症状与特定药物和第二种药物添加后的一段时间相联系。治疗的目的是控制青光眼，而通常的测量方法是通过每只眼睛的视野测试。由于青光眼患者使用双眼来发挥功能，我们希望探索像视野测试这样的视觉功能测量之间的关系，当使用两只眼睛进行评估时 双眼，结合分别在每只眼睛上进行的视觉功能测量的方法，这是临床上典型的测试，以表示双眼视觉功能。所有这些目标都依赖于从600多名参与者那里收集的数据，这是一项青光眼初始治疗的临床试验，即协作性初始青光眼治疗研究。这项拟议的研究与国家眼科研究所的目标密切相关，以支持关于失明眼病、视觉障碍、视觉功能机制、视力保护以及部分视力或失明个人的特殊健康问题和需求的应用临床研究。

 DESCRIPTION (provided by applicant): Glaucoma is one of the leading causes of visual impairment and blindness worldwide and in the United States. While glaucoma is usually a condition that affects both eyes, clinical assessments of its impact on patients in typical eye car settings are performed on each eye separately. This belies the fact that people affected by glaucoma function with both eyes, and treatments used to control glaucoma may impact on the person rather than only on the eye, even when those treatments are administered to only one eye. The overarching aim of the proposed research in this grant application is to assess the impact of glaucoma on the person rather than on the eye. Glaucoma has been associated with depression, and so we intend to evaluate depression in newly diagnosed glaucoma patients from the time of diagnosis through 9 years of follow-up during treatment, with respect to its prevalence and predictors. The typical approach to treating glaucoma involves frequent administration (often two or three times per day) of one or more topical medications (eye drops) to control eye pressure. Each type of medication has a unique set of potential symptoms associated with its use. We wish to relate reported ocular and systemic symptoms over time for a specific medication and after the addition of a second medication. The purpose of treatment is to control glaucoma, and the way that is typically measured is by means of a visual field test of each eye. Since a person with glaucoma uses both eyes to function, we wish to explore the relationship of visual function measures like the visual field test, when it is assessed using both eyes, with methods used to combine visual function measures taken on each eye separately, which is the typical test done in the clinic, to represent binocular visual function. All of these aims depend on data collected from over 600 participants in a clinical trial of initial treatments for glaucoma, the Collaborative Initial Glaucoma Treatment Study. The proposed research relates closely with the goals of the National Eye Institute, to support applied clinical research concerning the blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and needs of individuals who are partially-sighted or blind.